Circulating Cell-Free Tumor DNA Market

Circulating Cell-Free Tumor DNA Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Cancer

by

The Circulating Cell-Free Tumor DNA Market is estimated to be valued at US$ 6.1 billion in 2023 and is expected to exhibit a CAGR of 22.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The Circulating Cell-Free Tumor DNA market involves the analysis of cell-free DNA in the bloodstream to detect and monitor cancer. This non-invasive method provides valuable insights into the genetic alterations associated with tumors, allowing for early diagnosis, treatment selection, and monitoring of treatment response in cancer patients. The market includes products such as blood collection tubes, DNA extraction kits, PCR reagents, and sequencing instruments, among others. These products find application in oncology research institutes, hospitals, diagnostic laboratories, and pharmaceutical companies.

Market Dynamics:
The growth of the Circulating Cell-Free Tumor DNA market can be attributed to the increasing prevalence of cancer worldwide. The rising burden of cancer has resulted in a growing demand for early and accurate detection methods, which drives the adoption of liquid biopsy techniques such as circulating tumor DNA analysis. Furthermore, technological advancements in sequencing techniques, such as next-generation sequencing and droplet digital PCR, have significantly improved the sensitivity and specificity of tumor DNA detection, further fueling market growth. Additionally, the non-invasive nature of liquid biopsy offers a less invasive alternative to traditional tissue biopsy, contributing to the market’s expansion.

Segment Analysis:
In the circulating cell-free tumor DNA market, the key segments can be categorized based on the application, end-user, and region.

One of the dominating segments in this market is the cancer screening and early detection segment. This segment is expected to dominate the market due to the increasing prevalence of cancer globally and the growing importance of early diagnosis for better patient outcomes. Moreover, advancements in technology have led to the development of non-invasive liquid biopsy tests, which use the circulating cell-free tumor DNA to detect cancer at an early stage. These factors contribute to the dominance of the cancer screening and early detection segment in the circulating cell-free tumor DNA market.

PEST Analysis:

Political: The political landscape can impact the circulating cell-free tumor DNA market through regulations and policies related to healthcare, research, and development. Government initiatives and funding for cancer research can drive the adoption of circulating cell-free tumor DNA tests.

Economic: Economic factors, such as disposable income and healthcare expenditure, play a crucial role in the market’s growth. Higher disposable income allows individuals to afford expensive tests, while increased healthcare expenditure supports the development and adoption of advanced technologies in the healthcare sector.

Social: The social factors impacting the market include the increasing awareness of cancer and the importance of early diagnosis. Moreover, the aging population and changing lifestyle patterns contribute to the rising prevalence of cancer, driving the demand for circulating cell-free tumor DNA tests.

Technological: Technological advancements in genomics and molecular diagnostics have revolutionized the detection and monitoring of cancer. The development of next-generation sequencing technologies and improved bioinformatics tools has enabled the detection of genetic alterations in circulating cell-free tumor DNA, making it a promising tool in cancer diagnostics.

Key Takeaways:
The Global Circulating Cell-Free Tumor DNA Market Size is expected to witness high growth, exhibiting a CAGR of 22.9% from 2023 to 2030. This growth can be attributed to the increasing prevalence of cancer globally and the growing importance of early detection for better patient outcomes. Additionally, technological advancements in genomics and molecular diagnostics have fueled the development of non-invasive liquid biopsy tests based on circulating cell-free tumor DNA.

From a regional perspective, North America is projected to be the fastest-growing and dominating region in the circulating cell-free tumor DNA market. This can be attributed to the presence of key market players, well-established healthcare infrastructure, and high healthcare expenditure in the region.

Key players operating in the circulating cell-free tumor DNA market include Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, and Thermo Fisher Scientific.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it